Gastroenterology Fellowship – Massachusetts General Hospital, Boston, MA
Hepatology Clinical Fellows
M.D., Ph.D. - Albert Einstein College of Medicine, Yeshiva University, Bronx, NY
Internal Medicine Residency - Einstein Medical Center Philadelphia, Philadelphia, PA
I was drawn to NIH because of their unique approaches to answer basic biological questions through clinical research trials. One of my research interests is to understand the role of liver immune system in pathogenesis of liver diseases, especially liver cancer and autoimmune liver diseases. The unique immune tolerogenicity of liver is evident from the low-level immunosuppression required in a HLA-mismatched, orthotopic liver recipient, contrary to other solid organ transplantations. Additionally, the liver confers the same immunotolerance to the kidney in recipients of dual liver-kidney transplant. This phenomenon shows that the liver can modulate systemic immune response but may be predisposed to chronic infection and malignancy. Researchers have explored different methods to modulate the hepatic immune system, and our lab recently showed that gut microbiota-dependent changes in bile acid composition can modulate immune surveillance of liver tumors in a murine model. My goal is to dissect the molecular mechanism using tissue culture and mouse model, and to correlate these findings in human. This research may lead to novel therapies for primary and metastatic liver cancers.
M.D. University of Hawaii John A. Burns School of Medicine.
Residency SUNY Upstate Medical University
Current interests include long term follow up of patients treated for Hepatitis C, Fontan associated liver disease and fatty liver disease in unique patient populations. I am also matriculating to the NIH-Duke Master's Program in Clinical Research.
M.D.- Kakatiya Medical College, India
Research Interest: Noncirrhotic Portal Hypertension
My research interests include non-cirrhotic portal hypertension, viral hepatitis, alcohol related liver disease, non-alcoholic fatty liver disease and association of liver disease with severe combined immunodeficiency. Working at the NIH also provides me the unique opportunity to study the pathogenesis of hepatopathy in patients who had a Fontan procedure for correction of a congenital heart defect.
Non-cirrhotic portal hypertension, characterized by portal hypertension in the absence of cirrhosis or synthetic liver dysfunction, is an incompletely understood disease process without any definitive treatment regimen. Our team at the NIH aims to is working to provide a better understanding of the natural history and pathogenesis of non-cirrhotic portal hypertension with the hope of developing a reliable method of treatment.
Hepatitis B does not have a cure today due to the persistence of covalently closed circular DNA. Our goal is to conduct a proof of concept pilot study to explore the effect of removal of HBsAg by administration of HBIg and peginterferon alfa-2a on HBV-specific adaptive immunity and immune control.
M.D - Université de Montréal, Montreal, Canada
Internal Medicine Residency - Université de Montréal, Canada
Gastroenterology Fellowship - Université de Montréal, Canada
Recently, I was part of the liver unit at the Centre hospitalier de l’Université de Montréal (CHUM) before beginning my hepatology fellowship at the NIDDK.
During my stay at the LDB, I plan on taking part in clinical research trials focusing on novel pharmaceutical approaches for viral hepatitis and to pursue my interest in auto-immune liver disease as well as hepatic involvement in systemic diseases.
Bethesda, MD 20892
Bethesda, MD 20892